Income Statement Presentation 2023

Major pending approvals 2022 US Polivy EU China Evrysdi Evrysdi RG7596 1L DLBCL (US) Filed Aug 2022 Tecentriq SC RG7916 SMA presymptomatic pediatric <2mo RG7916 SMA presymptomatic pediatric <2mo RG6264 Filed Nov 2021 RG6413+ RG7446 all approved indications RG6412 Filed Nov 2022 glofitamab Ronapreve* SARS-CoV-2 hospitalized Filed Jan 2022 glofitamab RG6264 RG6026 3L+ DLBCL RG6026 3L+ DLBCL RG6107 Filed Dec 2022 Filed April 2022 RG1569 Actemra SS-ILD Filed June 2022 Phesgo HER-2+ BC Filed July 2022 crovalimab PNH Filed Aug 2022 glofitamab RG6026 Filed Aug 2022 3L+ DLBCL Filed Dec 2022 Tecentriq SC RG7446 all approved indications Filed Nov 2022 Status as of February 2, 2023 New Molecular Entity (NME) Additional Indication (Al) Oncology/Hematology Immunology Infectious Diseases Japan-Chugai Phesgo HER-2+ BC/CC Filed Sept 2022 Roche Metabolism Neuroscience Ophthalmology Other PDS-Port Delivery System with ranibizumab SC=Subcutaneous *Ronapreve (casirivimab+imdevimab also known as REGEN-COV in the US) developed in collaboration with Regeneron Pharmaceuticals 81

View entire presentation